Dr Advani presents long-term follow-up results from the SWOG 1318 trial, evaluating the combination of dasatinib, prednisone, and blinatumomab in elderly patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).

The study demonstrated impressive outcomes, including high remission rates, with factors such as the number of blinatumomab cycles and the presence of extramedullary disease influencing survival.

Translational studies on chromatin accessibility may also help identify new predictors of overall survival.